Piramal Pharma Reports Mixed Financial Results, Highlighting Cash Flow Growth Amid Declining Profits in June 2025

Piramal Pharma has recently reported its financial results for the quarter ending June 2025, revealing notable shifts in its performance metrics. The company's evaluation has undergone a revision, reflecting a score adjustment from 18 to -9 over the past three months.
On a positive note, Piramal Pharma has achieved its highest annual operating cash flow at Rs 548.77 crore, indicating a consistent growth trend in cash revenues from its business operations over the last three years. This aspect highlights the company's ability to generate cash from its core activities.

Conversely, several key financial indicators have shown significant challenges. The profit before tax less other income (PBT) has registered at Rs -158.16 crore, marking a substantial decline compared to the average of the previous four quarters. Similarly, the profit after tax (PAT) stands at Rs -102.44 crore, reflecting a considerable drop from the prior averages. Additionally, net sales have decreased to Rs 1,933.71 crore, the lowest in the last five quarters, further emphasizing the negative trends in the company's financial performance.

Overall, Piramal Pharma's recent financial results illustrate a complex landscape of both strengths and weaknesses, leading to an adjustment in its evaluation.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.